Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Randomized, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of RBN-3143 in Healthy Subjects and as Open-Label in Patients With Atopic Dermatitis Subjects

NCT05215808 is registered in ClinicalTrials.gov with Ribon Therapeutics, Inc. as lead sponsor.

NCT NCT05215808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Randomized, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of RBN-3143 in Healthy Subjects and as Open-Label in Patients With Atopic Dermatitis Subjects
Lead sponsor
Ribon Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
March 7, 2022
Completion date
September 30, 2024
Enrollment
72 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis